Scholar Rock Holding Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

David Hallal

Amministratore delegato

US$400.8k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.8yrs
Proprietà del CEO	0.3%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	9.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

David Hallal (58 yo)

7.8yrs

Mandato

US$400,849

Compensazione

Mr. David L. Hallal is Co-Founder of ElevateBio, LLC and has been its Executive Chairman since April 2025. He served as Chairman and Chief Executive Officer of ElevateBio LLC until April 2025. He is CEO of...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
David Hallal	CEO & Chairman of the Board	no data	US$400.85k	0.31% € 7.8m
Mo Qatanani	Chief Scientific Officer	1.3yrs	US$2.96m	0.021% € 541.7k
Akshay Vaishnaw	President of R&D	less than a year	US$281.26k	0.010% € 252.8k
Jing Marantz	Chief Medical Officer	2.5yrs	US$3.08m	0.013% € 335.8k
Vikas Sinha	Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Robert Woods	Chief Operating Officer	less than a year	Nessun dato	Nessun dato
Erin Moore	Interim Principal Financial & Accounting Officer	5.6yrs	Nessun dato	0.087% € 2.2m
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	Nessun dato	Nessun dato
Junlin Ho	General Counsel & Corporate Secretary	5.2yrs	US$2.13m	0.10% € 2.6m
Caryn Parlavecchio	Chief Human Resources Officer	3.8yrs	Nessun dato	0.062% € 1.6m
Edward Myles	Senior Advisor	less than a year	US$2.01m	0% € 0
Lisa Price	Senior Vice President of Human Resources	no data	Nessun dato	Nessun dato

1.3yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 2QK non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
David Hallal	CEO & Chairman of the Board	7.8yrs	US$400.85k	0.31% € 7.8m
Akshay Vaishnaw	President of R&D	11.3yrs	US$281.26k	0.010% € 252.8k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	11.5yrs	US$283.35k	0.039% € 1.0m
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	Nessun dato
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	8.6yrs	US$288.76k	0.0095% € 240.9k
Leonard Zon	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Daniel Rifkin	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Kristina Burow	Independent Director	10.8yrs	US$282.94k	0.0056% € 142.7k
Joan Massague	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Scott L. Friedman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Barry Coller	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Joshua Reed	Independent Director	4.2yrs	US$288.76k	0% € 0

9.7yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2QK sono considerati esperti (durata media dell'incarico 9.7 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/05/20 17:29
Prezzo dell'azione a fine giornata	2025/05/20 00:00
Guadagni	2025/03/31
Guadagni annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Scholar Rock Holding Corporation è coperta da 16 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Madhu Kumar	Baird
Etzer Darout	BMO Capital Markets Equity Research
Guyn Kim	BMO Capital Markets Equity Research

Scholar Rock Holding Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Scholar Rock Appoints Vikas Sinha as Chief Financial Officer

Scholar Rock Holding Corporation, Annual General Meeting, May 22, 2025

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock Announces the Appointment of Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Recent updates

Scholar Rock Appoints Vikas Sinha as Chief Financial Officer

FDA Grants Priority Review for Biologics License Application (BLA) and Ema Accepts Marketing Authorisation Application (MAA) for Apitegromab as A Treatment for Spinal Muscular Atrophy

Scholar Rock Holding Corporation, Annual General Meeting, May 22, 2025

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock Holding Corporation Announces Executive Changes

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Scholar Rock Announces the Appointment of Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

New major risk - Financial position

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Senior VP & Head of Research recently sold €268k worth of stock

New major risk - Revenue and earnings growth

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: US$2.26 loss per share (vs US$3.59 loss in FY 2021)

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock Announces Chief Executive Officer Changes

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Scholar Rock Holding Corporation Provides Pipeline Updates

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.76 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Forecast to breakeven in 2025

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020)

Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy

Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors

Full year 2020 earnings released: US$2.81 loss per share (vs US$1.85 loss in FY 2019)

Revenue misses expectations

New 90-day high: €50.00

Scholar Rock Announces Executive Promotions

New 90-day high: €47.40

New 90-day high: €43.80

Third quarter 2020 earnings released: US$0.79 loss per share

Revenue misses expectations

New 90-day high: €31.80

Scholar Rock Holding Corporation to Report Q2, 2020 Results on Aug 07, 2020